Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era

View ORCID ProfileAlexandra Savinkina, Alyssa Bilinski, View ORCID ProfileMeagan C. Fitzpatrick, View ORCID ProfileA. David Paltiel, Zain Rizvi, View ORCID ProfileJoshua A. Salomon, Tommy Thornhill, Gregg Gonsalves
doi: https://doi.org/10.1101/2022.02.08.22270465
Alexandra Savinkina
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT
2Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
MSPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandra Savinkina
  • For correspondence: alexandra.savinkina@yale.edu
Alyssa Bilinski
3Departments of Health Services, Policy, and Practice & Biostatistics, Brown University School of Public Health, Providence, RI
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan C. Fitzpatrick
4Center for Vaccine Development and Global Health, University of Maryland School of Medicine
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meagan C. Fitzpatrick
A. David Paltiel
2Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
5Department of Health Policy and Management, Yale School of Public Health, New Haven, CT
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. David Paltiel
Zain Rizvi
6Public Citizen, Washington, DC
JD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua A. Salomon
7Department of Health Policy, Stanford University, Palo Alto, CA USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joshua A. Salomon
Tommy Thornhill
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT
2Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregg Gonsalves
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT
2Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries has received a full primary vaccine series, compared to over 70% of the population of high-income nations.

Methods We used economic and epidemiologic models, parameterized with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programs in low and lower-middle income countries (LIC/LMIC) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2. Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up, and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs.

Findings Global scale up of vaccination to provide two doses of mRNA vaccine to everyone in LIC/LMIC would cost $35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of $26,900 per death averted. Scaling up vaccination to provide three doses of mRNA vaccine to everyone in LIC/LMIC would cost $61.2 billion and avert 1.5 million deaths from COVID-19 at a cost of $40,800 per death averted. Lower estimated infection fatality ratios, higher cost-per-dose, and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis.

Interpretation Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life (VSL). Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: MCF gratefully acknowledges funding from the National Institutes of Health (5K01AI141576). AB and JAS were supported by the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02; AB, JAS).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This study used only publicly available data sources.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 09, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era
Alexandra Savinkina, Alyssa Bilinski, Meagan C. Fitzpatrick, A. David Paltiel, Zain Rizvi, Joshua A. Salomon, Tommy Thornhill, Gregg Gonsalves
medRxiv 2022.02.08.22270465; doi: https://doi.org/10.1101/2022.02.08.22270465
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era
Alexandra Savinkina, Alyssa Bilinski, Meagan C. Fitzpatrick, A. David Paltiel, Zain Rizvi, Joshua A. Salomon, Tommy Thornhill, Gregg Gonsalves
medRxiv 2022.02.08.22270465; doi: https://doi.org/10.1101/2022.02.08.22270465

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)